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Losoxantrone is a DNA intercalator that was developed with the potential to replace anthracyclines. The recommended single
agent dose of losoxantrone is 50 mg m
72 every 3 weeks. We conducted a phase I study of losoxantrone and a ﬁxed dose of
cyclophosphamide on a q3 weekly schedule. Forty-nine patients were enrolled, of which 46 were evaluable for toxicity. The
dose-limiting toxicity was neutropenia at the maximum tolerable losoxantrone dose of 45 mg m
72. With granulocyte colony-
stimulating factor support, signiﬁcant further dose escalation of losoxantrone was achieved. Cardiotoxicity was seen with
cumulative dosing. Pharmacokinetics of losoxantrone revealed linear kinetics and triphasic clearance, with signiﬁcant
interpatient variability. No objective responses were seen in this study. Neutropenia was dose-limiting in this combination with
or without granulocyte colony-stimulating factor support. The recommended dose for further testing is cyclophosphamide
500 mg m
72 followed by losoxantrone 95 mg m
72 with granulocyte colony-stimulating factor support.
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Losoxantrone (CI-941) is an anthrapyrazole cytotoxic drug that
acts through DNA intercalation and topoisomerase II inhibition,
resulting in single and double stranded DNA breaks (Fry et al,
1985; Showalter et al, 1987; Leteurtre et al, 1994). Unlike anthracy-
clines, it does not form reactive free radicals with NADPH, and
therefore theoretically should have less propensity for cardiotoxicity
through this mechanism (Graham et al, 1987). Losoxantrone
demonstrated impressive cytotoxic activity in a broad range of
tumour cell lines (Leopold et al, 1985). Accordingly, losoxantrone
was selected for further development with the anticipated potential
to replace anthracyclines through a more favourable therapeutic
index.
Although anthracycline mediated cardiotoxicity is multifactorial,
the major mechanism is likely free-radical-mediated myocyte
damage (Doroshow, 1986; Kesavan et al, 1996). Although initial
experiments in a foetal heart model showed less cardiotoxic effects
than doxorubicin (Fagan et al, 1984; Graham et al, 1987; Fisher
and Patterson, 1992), more recent toxicological data in hyperten-
sive rats showed similar histological features and no signiﬁcant
differences in severity of cardiac damage in the two agents
(Herman et al, 1998). In phase I trials the main dose-limiting toxi-
city was neutropenia, and a dose of 50 mg m
72 q3 weeks bolus
infusion was recommended for further testing (Foster et al,
1992). Cardiotoxicity was reported to be uncommon. In phase II
trials losoxantrone showed promising clinical activity against
advanced breast cancer with a 43–63% response rate (Talbot et
al, 1991; Calvert et al, 1994). In these studies, no clinically signiﬁ-
cant cardiac toxicity was observed. Therefore, further studies to
develop losoxantrone were taken to identify active combinations
with established agents like paclitaxel (Diab et al, 1999) and cyclo-
phosphamide. Cyclophosphamide in combination with doxo-
rubicin is at present the standard treatment for breast cancer. In
addition, cyclophosphamide also has an important role in high
dose chemotherapy with stem cell transplantation regimens. These
were the basis for conducting this phase I trial of cyclophospha-
mide combined with losoxantrone.
MATERIALS AND METHODS
Eligibility criteria
The study opened in October 1992 and closed in September 1996
to patient accrual. Patients 18 years or older with histologically or
cytologically proven solid malignancies refractory to standard
chemotherapy or for which no standard chemotherapy exists were
eligible if they fulﬁlled the other entry criteria which included:
World Health Organization (WHO) performance status 0–2, life
expectancy at least 8 weeks, adequate renal (serum creatinine
42m gd l
71), hepatic (bilirubin 41.5 mg dl
71), haematologic
function (leukocytes 53.0610
9 l
71, absolute neutrophil count
51.5610
9 l
71, platelet count 5100610
9 l
71) and cardiac func-
tion (deﬁned by baseline LVEF 545% by multiple gated
acquisition scan with no decrease 510% in the recent 6 months).
Patients with myocardial infarction in the past year, congestive
cardiac failure, unstable angina, cardiomyopathy, ventricular
arrhythmias on treatment or previous treatment with cumulative
doses of doxorubicin more than 300 mg m
72 or mitoxantrone
more than 125 mg m
72 were excluded. Patients should not have
received cytotoxic, hormonal therapy or radiotherapy within 3
weeks of study treatment (6 weeks for nitrosoureas and mitomycin
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these agents. Other exclusion criteria included severe active medical
conditions, pregnancy or lactation. A signed written informed
consent was obtained for all patients according to federal and insti-
tutional guidelines.
Treatment plan
Both drugs were administered by bolus intravenous infusions over
10 min each, with cyclophosphamide preceding losoxantrone.
Treatment was repeated every 3 weeks until tumour progression
or occurrence of unacceptable toxicity (as deﬁned by an absolute
fall in the left ventricular ejection fraction from baseline 415%
or below 40% or grade 4 nonhaematological toxicity) or at the
patient’s or physician’s discretion.
Cyclophosphamide dose was ﬁxed at 500 mg m
72 and losoxan-
trone dose was escalated from a starting dose of 30 mg m
72
through 40, 45 and 50 mg m
72. A minimum of three patients were
treated at each dose level. Dose-limiting toxicity (DLT) was deﬁned
as grade 4 neutropenia lasting more than 5 days or associated with
fever; grade 4 thrombocytopenia; or grade 3 or 4 non-haematologi-
cal toxicity (excluding nausea and vomiting) occurring in the ﬁrst or
second cycle of treatment. If a DLT was observed, two additional
patients were treated at that dose-level. Dose escalation proceeded
only if less than three out of ﬁve patients had dose-limiting toxicity.
The dose level at which three or more patients experienced DLT
deﬁned the maximum tolerated dose (MTD). No intrapatient dose
escalation was allowed, but patients who experienced DLT were
allowed further treatment if clinically indicated with dose reduction
to the next lower level. Dose delay for recovery from toxicity was
also allowed up to 3 weeks from the scheduled day of treatment.
Three stages of the study were planned: Initial stage without G-
CSF support, second stage with G-CSF support if neutropenia was
dose-limiting, and single-agent losoxantrone with G-CSF support
in the third stage. G-CSF was administered subcutaneously at
5 mg kg day
71 from day 3 of the cycle until neutrophil recovery past
nadir to more than 1.5610
9 l
71.
Drug administration
Losoxantrone was supplied by DuPont Pharmaceuticals Company
(Wilmington, DE, USA) in vials containing 25 mg of lyophilized
powder. Each vial was reconstituted with 2.5 ml of sterile water
for injection to give a concentration of 10 mg ml
71. The calculated
total dose for a patient was then further diluted with normal saline
to a total volume of 50 ml and administered by infusion over
10 min. All patients received prophylactic antiemetics with seroto-
nin antagonists.
Cyclophosphamide (Cytoxan
1) was supplied by the University
of Chicago Hospital Pharmacy and administered over 10 min infu-
sion. G-CSF (Neupogen
1, Amgen, Thousand Oaks, USA) was
supplied as ampules containing 0.6 mg of cytokine in 2 ml of ster-
ile water.
Evaluation
All patients had baseline history, physical examination, complete
blood counts, electrolytes, blood urea nitrogen, creatinine, liver
function tests, electrocardiogram, multiple gated acquisition scan
(MUGA) and tumour measurements by relevant radiological inves-
tigations. Toxicity assessment was done weekly during the study
using the National Cancer Institute Common Toxicity Criteria
Version 1 for grading. Complete blood counts were performed
twice weekly and more frequently during grade 3 or 4 myelosup-
pression. Blood chemistries were repeated weekly. MUGA scan
and tumour assessments were repeated after every two cycles.
Response was measured according to the World Health Organiza-
tion criteria for tumour response (Miller et al, 1981).
Pharmacokinetics and pharmacodynamics
Pharmacokinetic sampling for losoxantrone plasma concentrations
were obtained at the following time points during the ﬁrst cycle of
chemotherapy: at baseline and 5, 10, 20, 30, 40, 65 min and at 1.5,
2, 3, 4, 6, 8, 12, 14, 24, 30, 48, 72 and 96 h after the start of the
losoxantrone infusion. The blood samples were drawn from an
indwelling intravenous cannula from the arm contralateral to that
used for drug infusion into plastic centrifuge tubes containing
citrate buffer, and centrifuged at 3300 revolutions per minute for
15 min. The resulting plasma supernatant was then separated and
stored at 7208C until analysis. Losoxantrone plasma levels were
determined using a validated high-performance liquid chromato-
graphic (HPLC) method (Graham et al, 1989). Calibration curves
were linear within the concentration ranges relevant to this study,
with precision and accuracy within 15% and mean extraction efﬁ-
ciency of 99.7+12.7%.
Non-compartmental and compartmental methods were used to
derive pharmacokinetic parameters for losoxantrone (Gibaldi and
Perrier, 1982). Using the linear trapezoidal method as implemented
in PK-IMS Version 2.0 software (DuPont Pharmaceuticals
Company), area-under-the plasma concentration-time curve
(AUC) extrapolated to inﬁnity, terminal half-life (T1/2), mean resi-
dence time (MRT), volume of distribution at steady-state (Vss) and
systemic clearance (CL) were calculated. Compartmental methods
were used to ﬁt losoxantrone concentrations using the software
WINNONLIN (Pharsight Corporation, Cary, NC, USA). The phar-
macokinetic parameters of losoxantrone from this combination
study were compared (however, no statistical comparisons were
made between these across study data) with those obtained in
two single agent studies (Allen et al, 1991; Graham et al, 1992),
and a study where losoxantrone was administered along with pacli-
taxel (Diab et al, 1999).
Pharmacodynamic analysis explored the relationship between
losoxantrone exposure and toxicity or response. A sigmoidal Emax
model was used to ﬁt the percentage change in neutrophils and
the losoxantrone AUC using the equation:
% drop in ANC  100  AUCH=AUCH  AUC50
H
where H is the Hill constant that describes the sigmoidicity of the
curve, AUC50 is the area-under-the concentration-time curve at
half-maximal effect. Percentage fall in LVEF was correlated with
cumulative dose per square metre of losoxantrone and actual cumu-
lative dose of losoxantrone using linear regression analysis. The F
statistic was tested to determine the signiﬁcance of correlation.
RESULTS
Forty-nine patients enrolled in the study, of which 46 were evaluable
fortoxicity;theircharacteristicsareshowninTable1.Twoinevaluable
patients did not receive treatment after enrolment due to withdrawal
of consent and one was ineligible on the day of ﬁrst treatment due to
elevation of bilirubin. The patient population consisted of patients
who were fairly heavily pretreated with chemotherapy, of which seven
patients had received prior anthracycline therapy; ﬁve patients had
prior doxorubicin (maximum 240 mg m
72), one patient had liposo-
mal doxorubicin 1200 mg m
72, and one patient had received
44 mg m
72 of mitoxantrone.
Ninety-ﬁve cycles of treatment were administered with a median
of two cycles per patient over 12 dose levels of losoxantrone,
ranging from 30 to 150 mg m
72 of losoxantrone (Table 2). The
cumulative dose of losoxantrone ranged from 60 to 570 mg m
72,
with a median of 225 mg m
72.
Haematological toxicity (Table 2)
Table 2 shows the grade 3 or 4 haematological toxicities at all the
dose levels. Dose-limiting neutropenia was observed at doses of 45
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72, with three out of seven patients and two out of
three patients experiencing grade 4 neutropenia lasting more than
5 days, respectively. Therefore the MTD was reached at
45 mg m
72 of losoxantrone, which is close to its recommended
single agent dose. G-CSF ameliorated neutropenia and allowed
signiﬁcant further escalation of losoxantrone dose to
125 mg m
72, at which three out of ﬁve patients developed febrile
neutropenia which deﬁned this dose as the new MTD. The next
lower dose cohort treated at 110 mg m
72 was expanded to include
a total of eight patients, of which three fulﬁlled the criteria for
DLT; two experienced grade 4 neutropenia lasting more than 5
days and one patient had febrile neutropenia. Two further dose
levels of losoxantrone without cyclophosphamide, 125 and
150 mg m
72 were studied, but the study was terminated before
the MTD was reached because of a sponsor decision. However,
both patients treated at 150 mg m
72 experienced DLT, one with
febrile neutropenia and the other with grade 3 fatigue. No DLTs
were observed at the next lower dose of 125 mg m
72 without
cyclosphosphamide. Anaemia was more frequent at the higher dose
levels, with two patients developing grade 3 anaemia at 110 and
125 mg m
72 respectively. Grade 3 thrombocytopenia occurred in
one patient at 95 and 110 mg m
72 of losoxantrone, respectively.
A dose intensity analysis using data from at least two cycles of
treatment showed that 87–91% of the scheduled dose intensity
of losoxantrone could be administered at 80 and 95 mg m
72
respectively, supporting the tolerability of these doses (Hryniuk,
1996).
Nonhaematological toxicity
Fatigue, nausea and vomiting grade 2 or less were observed at most
dose levels and ameliorated by symptomatic measures. Grade 3
fatigue was experienced by one patient at 150 mg m
72 of losoxan-
trone. A serious but previously unreported toxicity was interstitial
lung disease in a 73-year old male patient with metastatic prostatic
cancer with no evidence of pulmonary metastases or prior thoracic
radiotherapy. He was treated at a dose of 110 mg m
72 of losoxan-
trone (cumulative dose of losoxantrone of 330 mg m
72) and
developed progressive dyspnea, fever, and dry cough 1 week after
the third dose. High resolution CT scan of the lung showed diffuse
bilateral upper lobe alveolar inﬁltrates. Transbronchial biopsy did
not reveal any infective etiology. Despite steroids and oxygen treat-
ment, the pulmonary process progressed and he died from
respiratory failure 3 months after the last dose of losoxantrone.
An autopsy performed showed diffuse alveolar damage.
Cardiac toxicity
Twenty-three patients had paired MUGA assessments, having
received at least two cycles of chemotherapy treatment. Figure 1
shows the change of the LVEF as a function of the cumulative dose
of losoxantrone. Drop in the left ventricular ejection fraction of
more than 10% from the baseline was observed in seven (30%)
patients at dose levels 50, 65, 125 and 150 mg m
72 of losoxan-
trone. In one patient, clinically apparent cardiac failure developed
2 months after cessation of losoxantrone treatment. This patient
was a 48-year old female with thyroid cancer and no prior anthra-
cycline therapy who received a cumulative dose of 570 mg m
72 of
losoxantrone, the highest in this study. Transthoracic echocardio-
gram showed an estimated LVEF of 20% and global hypokinesia,
which was a signiﬁcant drop from the baseline of 59%. Linear
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Table 2 Worst haematological toxicity by dose level – number of patients (grade of toxicity)
Dose level of Number of
losoxantrone patients evaluable Leucocytes Neutrophils Platelets Hb DLTs
30 3 1(3) 1(3)
40 3 1(3), 1(4) 1(3), 1(4)
45 7 3(3), 3(4) 1(3), 5(4) 1(3) 3 Gr 4 ANC45 days
50 3 2(3) 2(4) 2 Gr 4 ANC45 days
50G 3
65G 3 1(3)
80G 3 1(4) 1(4) 1 Gr 4 ANC45 days
95G 3 2(3), 1(4) 1(3), 2(4) 1(3) 1 Gr 4 ANC45 days
110G 8 1(3), 7(4) 8(4) 1(3) 2(3) 2 Gr 4 ANC45 days
1 febrile neutropenia
125G 5 2(4) 1(3), 2(4) 2(3) 3 febrile neutropenia
125G* 3 1(3), 2(4) 1(3), 2(4)
150G* 2 1(3), 1(4) 2(4) 1 febrile neutropenia
1 Gr 3 fatigue
Gr=grade. G=granulocyte-colony stimulating factor. *Losoxantrone without cyclophosphamide.
Table 1 Patient characteristics (n=46)
Characteristic Number
Age 55
Median (range) (40–77)
Sex
M3 2
F1 4
PS
02 4
11 8
24
No. of doses 32
Median (range) (1–8)
Colon 13
Prostate 5
Head and neck 1
Thyroid 1
Unknown primary 3
Bile duct/gallbladder 2
NSCLC 7
Leiomyosarcoma 1
SCLC 3
Bladder 1
Breast 1
Liver 2
Mesothelioma 1
Gastric 1
Thyroid 2
Soft tissue sarcoma 1
Oesophageal 1
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British Journal of Cancer (2002) 86(4), 534–539 ã 2002 Cancer Research UKregression analysis showed a signiﬁcant relationship between cumu-
lative dose per m
2 (r=0.62, P=0.002) and actual dose (r=0.55,
P=0.007) with percentage change in LVEF. However, this positive
relationship was strongly dependent on the data point of the
patient with severe cardiac failure at a cumulative dose of
570 mg m
72 of losoxantrone. There was no signiﬁcant relationship
between the change in LVEF and the cumulative dose of prior
anthracycline therapy (r=0.14, P=0.2).
Response
No objective responses were observed in this study. Only one
patient had breast cancer that had prior treatment with cyclo-
phosphamide, doxorubicin and 5-ﬂuorouracil and paclitaxel, and
the patient had progressive disease after two treatment cycles on
this study.
Pharmacokinetic and pharmacodynamic analyses
First cycle losoxantrone pharmacokinetics were studied in 31
patients; all dose levels were studied except doses above
110 mg m
72. The pharmacokinetic parameters of losoxantrone
are listed in Table 3. A three compartmental model with intrave-
nous infusion input was found to optimally ﬁt data for
estimating the half-lives t1/2a, t1/2b and t1/2g and the central
compartment volume of distribution (Vc). Losoxantrone pharma-
cokinetics were characterised by a rapid distribution phase into
tissue with a t1/2a of *6–8 min, t1/2b of *1 h and with a
prolonged terminal half-life t1/2g of *36 h. Clearance was rapid
(average of 526+190 ml min m
72 and range of 442 to
735 ml min m
72), and steady state volume of distribution was
large (average of 989+583 l m
72 and range of 771 to 1465 l
m
72). There was large interpatient variability (% CV ranged from
30 to 60%) in the pharmacokinetics. Clearance appeared to be line-
ar across dose levels, as clearance did not correlate with dose
(r=0.16, P=0.38). A sigmoidal Emax model was used to demonstrate
the correlation between the per cent change in neutrophil count at
nadir in the ﬁrst cycle and losoxantrone AUC, with and without G-
CSF support. As shown (Figure 2), there was a shift of the curve to
the right with G-CSF support, with approximately tripling in the
value of AUC50 from 464 to 1474 ng h ml
71.
DISCUSSION
Neutropenia is the dose-limiting toxicity of a 3-weekly short infu-
sion schedule of cyclophosphamide and losoxantrone in this study.
We found that with a ﬁxed dose of cyclophosphamide of
500 mg m
72, a losoxantrone dose of 45 mg m
72 appeared to be
tolerable. G-CSF support allowed signiﬁcant dose escalation of
losoxantrone beyond its single-agent recommended phase II dose.
MTD was reached at a dose of 125 mg m
72 of losoxantrone, with
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Table 3 Pharmacokinetic parameters of losoxantrone
Losoxantrone dose (mg m
72) in combination with Losoxantrone dose (mg m
72) in combination with
500 mg m
72 cyclophosphamide 500 mg m
72 cyclophosphamide and G-CSF
Parameter
a 30 (n=3) 40 (n=3) 45 (n=7) 50 (n=3) 50 (n=3) 65 (n=3) 80 (n=3) 95 (n=3) 110 (n=3)
AUC (mg×hm l
71) 1.1+0.2 1.5+0.9 2.0+1.0 1.5+0.6 2.0+0.5 2.1+0.7 3.1+0.1 2.3+0.6 4.0+0.2
CL (ml min m
72) 482+82 562+257 455+222 614+281 442+109 571+179 470+158 735+171 497+155
Vss (l m
72) 1468+1008 973+648 936+794 998+434 819+346 802+285 873+622 1334+440 771+274
T1/2 (h)
b 51+23 33+10 40+94 1 +19 41+83 4 +43 3 +24 24+23 6 +2
MRT (h) 50+29 27+83 2 +17 30+17 30+92 4 +33 9 +24 30+62 6 +3
T1/2, a (h)
b 0.10+0.06 0.13+0.02 0.16+0.02 0.15+0.01 0.14+0.3 0.10+0.06 0.18+0.02 0.04+0.02 0.16+0.09
T1/2, b (h)
b 1.0+3.2 1.2+0.5 1.3+0.3 1.5+0.3 1.4+0.3 0.7+0.6 1.3+0.1 0.4+0.2 1.9+0.9
T1/2, g (h)
b 42+20 31+11 40+10 36+29 43+63 2 +33 2 +13 30+73 8 +4
Vc (l m
72) 14.0+5.4 14.5+6.2 15.9+10.1 14.2+5.7 12.2+4.9 12.5+8.8 17.1+1.3 8.7+11.6 17.1+5.9
aValues are expressed and mean+s.d.
bHalf-lives are expressed as harmonic mean+pseudo s.d. of the jack-knife variance.
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(neutropenic fever) based on toxicities observed in the ﬁrst two
cycles. The next lower dose was therefore expanded to include eight
evaluable patients. However, myelosuppression was also signiﬁcant
at this dose level, and one death occurred after the third cycle due
to interstitial lung disease possibly attributable temporally to
chemotherapy. According to the deﬁnition of DLT in this study,
three of these toxic events were considered dose-limiting; two
patients developing grade 4 neutropenia lasting more than 5 days
and one patient with febrile neutropenia. Dose levels of 95 and
80 mg m
72 of losoxantrone were tolerable based on limited
number of patients treated. On this basis, we recommend a losox-
antrone dose of 95 mg m
72 when combined with
cyclophosphamide at a dose of 500 mg m
72 and G-CSF support
for further studies in phase II clinical trials. However, because
the study was terminated early due to a decision made by the
sponsor, we did not have the opportunity to gain more experience
with these dose levels. Without cyclophosphamide but with G-CSF,
the limited toxicity data on the three patients treated at
125 mg m
72 of losoxantrone suggested tolerability at this dose.
Therefore, G-CSF allows signiﬁcant extension of the therapeutic
index of losoxantrone.
Uncommon but severe delayed nonhaematological toxicities
were encountered, consisting of one patient with overt cardiac fail-
ure and another with acute alveolitis respectively. Although it was
not deﬁnite that losoxantrone was solely responsible for the acute
respiratory failure, histological changes found at autopsy was
reported as consistent with drug-induced alveolar damage.
Anthracenediones like mitoxantrone were developed as part of
the anthracycline analogue programme to identify agents with less
cardiotoxicity that maintained antitumour activity (Murdock et al,
1979). Mitoxantrone lacked the sugar moiety of anthracyclines, and
was selected on the basis of reduced capacity for free radical
production (Doroshow and Davis, 1983; Kharasch and Novak,
1983; Nguyen and Gutierrez, 1990). However, subsequent clinical
studies reported cardiotoxicity clearly associated with mitoxantrone
use (Unvererferth et al, 1983; Coleman et al, 1984; Mather et al,
1987). Anthrapyrazoles were also developed along this same strat-
egy of reduced cardiotoxicity through biochemical structural
modiﬁcation. However, the ﬁrst developed anthrapyrazole, pirox-
antrone, was reported to have signiﬁcant cardiotoxicity in phase
II trials in breast cancer (Ingle et al, 1994). In a phase II study
of an anthrapyrazole piroxantrone conducted by the Southwest
Oncology Group in advanced sarcoma, ﬁve of 23 patients had
reduced cardiac output after treatment, of which one was fatal
from congestive cardiac failure (Zalupski et al, 1993). Losoxantrone
has also been shown to be potentially cardiotoxic in clinical trials,
both as a single agent and in combination with paclitaxel. No rela-
tionship could be demonstrated between cumulative doses of
losoxantrone and change in LVEF in these prior reports. In our
study, a correlation between cumulative dose of losoxantrone and
reduction in LVEF was found. There are statistical ﬂaws in this
analysis, as the trial was not designed to elucidate the effect of
losoxantrone dose on changes in LVEF, the sample size was
limited, most patients only had two doses of treatment, and that
patients would have stopped the drug if a signiﬁcant drop in LVEF
had been detected. Above this, the relationship was also dependent
on a single outlier. Therefore, it is too preliminary to conclude that
cardiac toxicity from losoxantrone results from cumulative expo-
sure, and to suggest a cumulative dose at which this occurs.
However, this data we present would support the existing suspicion
that losoxantrone may also be cardiotoxic with cumulative doses.
Therefore, anthrapyrazoles have thus far not fulﬁlled the role of
replacing doxorubicin as an active DNA intercalator with minimal
or no cardiotoxicity.
The pharmacokinetics of losoxantrone in this study were similar
to previous reports. Overall losoxantrone pharmacokinetics was
characterized by rapid plasma clearance and a slow rate of elimina-
tion suggesting extensive tissue distribution. There was signiﬁcant
interindividual variability in clearance at the various dose levels,
as was noted in previous phase I clinical trials of losoxantrone,
with or without paclitaxel. No evidence of saturation in kinetics
was observed over the range of losoxantrone doses studied. In a
single agent phase I study in 23 patients (Graham et al, 1992),
where losoxantrone dose ranging from 5–55 mg m
72 was admi-
nistered, the plasma clearance averaged 417+194 ml min m
72.
In another single agent study in 13 patients (Allen et al, 1991),
where losoxantrone dose ranged from 4–36 mg m
72, the plasma
clearance averaged 220+89 ml min m
72. In the current study
where losoxantrone was given with cyclophosphamide, clearance
averaged 526+190 ml min m
72 and was linear over the dose
range of 30 to 110 mg m
72. In another phase I study of paclitaxel
at 135 mg m
72 and losoxantrone at 40 mg m
72, 13 patients were
studied and the clearance of losoxantrone was 341 ml min m
72
(Diab et al, 1999). These wide discrepancies in the clearance of
losoxantrone are likely due to large interindividual variability.
Indeed, this variability in losoxantrone clearance contributed to
the unsuccessful utilization of pharmacokinetically guided dose
escalation in the dose escalation process in the single agent phase
I studies (Graham et al, 1992). The reason for the larger interindi-
vidual variability of pharmacokinetics is not obvious and deserves
further study. Possible contribution from polymorphisms of meta-
bolizing enzymes like the glutathione-S-transferases which are
known to exhibit polymorphism and are involved in cyclophospha-
mide and doxorubicin metabolism, or variability in protein or
tissue binding deserves further study.
The per cent reduction in neutrophil nadir could be ﬁt in a
sigmoidal Emax model against AUC. Using this model, we could
show that addition of G-CSF allowed an approximately triple
AUC50 in a sigmoidal Emax model of the per cent reduction of
neutrophil nadir against AUC. This effect of G-CSF in improving
the therapeutic index of the combination may suggest a possible
future role for this combination in high dose chemotherapy proto-
cols. Further investigation of this appears warranted and may
revive interest in losoxantrone.
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